New Data from U.S. Post-Approval Study Assess Ischemic Stroke and Intracranial Hemorrhage Rates in People with Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban with Warfarin and Apixaban wi

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. IBM
3. PRIM
4. MU
5. DPZ
6. NAVN
7. DFTX
8. META
9. IMNN
10. ACN

Go back to New Data from U.S. Post-Approval Study Assess Ischemic Stroke and Intracranial Hemorrhage Rates in People with Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban with Warfarin and Apixaban wi

Piper Jaffray Raises Price Target on Johnson & Johnson (JNJ) Following 1Q Report

April 20, 2016 7:42 AM EDT

Piper Jaffray reiterated a Neutral rating on Johnson & Johnson (NYSE: JNJ), and raised the price target to $106.00 (from $105.00), following the company's 1Q earnings report. In Pharma, total sales of $8.2B and key drug sales were slightly better than estimates. The Medical Device segment generated revenue of $6.11B,... More